SAN FRANCISCO--(BUSINESS WIRE)-- Bodyport, a biomarker-guided digital therapeutics company on a mission to address complex chronic conditions, announced today the appointment of Jim Pursley to the company’s board of directors.

“I am excited to join the Bodyport Board of Directors as they reimagine care for patients living with complex chronic conditions. Bodyport’s focus on the patient has driven them to create an incredibly simple solution for patients with congestive heart failure. The Bodyport solution will reduce common monitoring complexities for patients while advancing how clinicians manage their patients,” Pursley said. “Bodyport is uniquely positioned to transform and improve the quality of life for millions of people around the globe. I am proud to support the company’s mission.”

Pursley is the President of Hinge Health and most recently served as Chief Commercial Officer for Livongo Health, where he was part of the founding executive team that built and grew Livongo into a global leader in consumer focused chronic condition management. He helped take them public in 2019, ultimately culminating in an $18.5 billion acquisition by Teladoc Health. Prior to Livongo, Pursley held executive leadership roles at Intel-GE Care Innovations and GE Healthcare. He earned his bachelor’s degree in Management Science & Information Systems from the Pennsylvania State University and an MBA from Northwestern University’s Kellogg School of Management. Additionally, Pursley is a Heart of Chicago Board member for the American Heart Association.

“Jim is an extremely valued addition as a proven leader in transforming how chronic conditions are managed. We are pleased to have Jim on the board as we move into commercialization and growth of our solution,” said John Lipman, CEO of Bodyport.

Pursley joins current board members and Bodyport Co-Founders Corey Centen and Sarah Smith; Bodyport CEO John Lipman; Garry Tan, Managing Partner at Initialized Capital; Stefan Pflanz, Executive Director at Boehringer Ingelheim Venture Fund; and Chair Phyllis Whiteley, PhD, of Playground Global.

About Bodyport

Bodyport is a biomarker-guided digital therapeutics company on a mission to address complex chronic conditions by embedding a sophisticated biomarker platform into simple, easy-to-use devices. Bodyport captures hemodynamic signals through the Cardiac Scale to power optimized interventions tailored to the patient. By not requiring a wearable device or surgical implant, the solution seamlessly integrates into a patient’s daily life.

Bodyport is focused on keeping patients with cardiorenal conditions healthier and out of the hospital. The company is tackling heart failure first to noninvasively assess heart function and fluid status in a single step at home. Bodyport is HIPAA compliant and has received SOC2 Type 2 certification.

Based in San Francisco, the company is backed by top-tier investors such as Boehringer Ingelheim Venture Fund, Playground Global, Initialized Capital, Y Combinator, and Rock Health.

For more information, visit bodyport.com and follow the company on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005081/en/